Delivery Order SPE2DB22D2007-SPE2DB25FJ3DH
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a $8,857.56 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract is for the supply of 4,557,985,673 units of the prescription drug Diclofenac Potassium 50 mg tablets in 100-count bottles. Amerisourcebergen holds a single-award Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 2025. This...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Diclofenac Potassium 50 mg tablets in 100-count bottles, with a ceiling value of $3,491.83 and a period of performance through July 9, 2025. The contract is a firm-fixed-price type and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the delivery of 4,565,784,264 units of Diclofenac Potassium 50 mg tablets in 100-count bottles. The contract has a firm-fixed price of $1,931.08 and a completion date of September 13, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of 4,565,878,672 units of diclofenac potassium 50 mg tablets, with a total ceiling value of $1,094.02. The contract has a completion date of September 20, 2024 and was awarded on September 19, 2024. It is a firm fixed-price, delivery order contract, with no set-aside designation. AmerisourceBergen holds a significant...
- The Defense Logistics Agency awarded a $723.60 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 tablets of 50mg Diclofenac Potassium. The order is to be fulfilled by Amerisourcebergen's Conshohocken, Pennsylvania facility by September 21, 2023 in support of the Defense Logistics Agency's medical supply needs. No set aside designation or subcontractors were indicated. The Defense Logistics Agency manages the global supply chain for the United States Department of...
- The Defense Logistics Agency Troop Support Medical awarded a $66,720 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 tablets of 50 mg diclofenac potassium. The place of performance is Amerisourcebergen's facility in Conshohocken, Pennsylvania. The period of performance is July 12-13, 2023. No subcontractors or set aside designations were identified. The Defense Logistics Agency manages the global supply chain for the United States Department of Defense,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of DICLOFENAC POT 50 MG TABLET 100S, a pharmaceutical product. The contract has a ceiling value of $1,075.24 and a period of performance through February 3, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,108.34 firm fixed-price delivery order is for the supply of DICLOFENAC POT 50 MG POWDR PKT 9S, a pharmaceutical product. The contract has a completion date of December 19, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The $1,008.61 firm-fixed-price delivery order is for the supply of 4,565,214,273 units of Diclofenac Sodium Delayed-Release 75 mg Tablets in 1,000-count sizes. The contract has an ultimate completion date of July 23, 2024 and does not utilize a set-aside. Amerisourcebergen is a major pharmaceutical distributor that holds several Indefinite...
- This federal contract award is for the delivery of DICLOFENAC SOD ER 100 MG TAB 100S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on December 30, 2024 with a ceiling value of $1,454.21. The contract is a Firm Fixed Price Delivery Order with a completion date of December 31, 2024. The contract is not designated with a set-aside. Amerisourcebergen Drug...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3DHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Diclofenac Potassium 50 mg tablets (100-count packages) with a ceiling value of $6,089.81. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The contract is structured as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. Performance is based in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This award supports the Defense Logistics Agency's Medical Supply Chain operations, delivering essential pharmaceutical products to military and veteran healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains an extensive portfolio of federal medical contracts covering a broad spectrum of therapeutic domains including pain management, antibiotics, specialty medications, and vaccines. The company's selection through open competition reflects its demonstrated capability to meet rigorous federal procurement standards and support critical defense health requirements globally through the DLA's pharmaceutical prime vendor program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 7/18/25 |